The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C–mutated metastatic colorectal cancer (CodeBreaK 301).
 
Tae Won Kim
Employment - Asan Medical Center
Research Funding - Genome Insight (Inst); Roche/Genentech (Inst)
 
Timothy Price
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck; Takeda
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - Amgen
 
Julieta Grasselli
Speakers' Bureau - Amgen; AstraZeneca; Merck; Pfizer; Sanofi
 
John Strickler
Stock and Other Ownership Interests - Triumvira Immunologics, Inc
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol Myers Squibb Foundation; Daiichi Sankyo/Astra Zeneca; GE Healthcare; GlaxoSmithKline; Ipsen; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Natera (Inst); Pfizer; Regeneron; Roche/Genentech; Sanofi; Seagen; Taiho Oncology; Takeda
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); Apollo Therapeutics; AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly (Inst); Erasca, Inc (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Lilly (Inst); Novartis; Pfizer; Quanta Therapeutics (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst)
Expert Testimony - Seagen
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD; Nippon Kayaku; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takata; Takeda; Yakult Honsha
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Gin Wai Kwok
No Relationships to Disclose
 
Suayib Yalcin
Stock and Other Ownership Interests - Humana; Pfizer
Honoraria - Gen
Consulting or Advisory Role - Amgen; Bayer; bms; Gen; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche
Speakers' Bureau - Bayer; Bayer; gen ilaç; Merck Serono; Novartis; Novartis; Pfizer; Roche
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Gen; Roche
 
Cynthia Obiozor
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Emily Chan
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Priya Gokani
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Incyte; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Merck; MSD K.K
Research Funding - Chugai Pharma; Lilly Japan; Otsuka; Taiho Pharmaceutical; Takeda